## First-Line Antibiotic Therapy for PID **Key Point:** WHO and most international guidelines recommend a triple-agent regimen to cover Neisseria gonorrhoeae, Chlamydia trachomatis, and anaerobic bacteria simultaneously. ### Recommended Regimen **Ceftriaxone + Doxycycline + Metronidazole** is the gold standard empirical therapy: | Drug | Dose | Spectrum | Rationale | |------|------|----------|----------| | Ceftriaxone | 250 mg IM once | N. gonorrhoeae, gram-negatives | Covers resistant gonorrhea | | Doxycycline | 100 mg PO BD × 14 days | Chlamydia, atypicals | Covers intracellular pathogens | | Metronidazole | 400–500 mg PO TDS × 14 days | Anaerobes, Trichomonas | Covers polymicrobial flora | **High-Yield:** This triple regimen achieves >90% microbiological and clinical cure rates. Doxycycline and metronidazole are continued for 14 days as outpatient oral therapy after initial parenteral ceftriaxone. ### Why This Combination? 1. **Broad spectrum:** Covers the three major pathogenic groups (gonorrhea, chlamydia, anaerobes) 2. **Resistance coverage:** Ceftriaxone is effective against penicillinase-producing N. gonorrhoeae (PPNG) 3. **Intracellular penetration:** Doxycycline reaches high concentrations in genital tissues 4. **Anaerobic coverage:** Metronidazole is essential for polymicrobial PID **Clinical Pearl:** If doxycycline is contraindicated (pregnancy, allergy), substitute with azithromycin 500 mg PO daily × 7 days, though this is less preferred due to emerging resistance. ### Alternative Regimens (if first-line contraindicated) - **Cefoxitin + probenecid + doxycycline + metronidazole** (if ceftriaxone unavailable) - **Clindamycin + gentamicin** (for hospitalized patients with severe disease) [cite:WHO Guidelines on STI Management 2016; Harrison 21e Ch 137] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.